Knight Therapeutics (TSE:GUD) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Knight Therapeutics has reported record revenues for the second quarter of 2024, showcasing a significant increase in both revenue and adjusted EBITDA compared to the previous year. The company credits the growth to its key promoted products and commercial execution in Canada and Latin America, despite a net loss and outflow of cash from operations.
For further insights into TSE:GUD stock, check out TipRanks’ Stock Analysis page.
